News & Stories
See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.
CMT Research Foundation to Benefit from a Portion of Ticket Sales from Alan Jackson’s 2024-2025 LAST CALL: ONE MORE FOR THE ROAD TOUR
The CMT Research Foundation (CMTRF), the only nonprofit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease* (CMT), is pleased to announce support from Alan Jackson's LAST CALL ONE MORE FOR THE ROAD TOUR 2024-2025 dates....
CMT Research Foundation Invests in Project to Test if a Commercially Available Drug is Effective Treatment for X-linked Charcot-Marie-Tooth Disease
The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT), has invested in a project led by Dr. Charles Abrams, a Professor in the Department of Neurology and Rehabilitation at the...
The CMT Research Foundation Makes Leadership Changes to Drive Next Phase of Growth; Names Peter de Silva as Board Chair
At its recent annual meeting, The CMT Research Foundation (CMTRF), a patient-led non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth disease* made changes in its leadership to support the next phase of the Foundation’s growth. The Foundation...
Dr. Riann Egusquiza Joins The CMT Research Foundation as Director of Research
Riann Egusquiza (ryan egg-uh-ski-tha) PhD has joined The CMT Research Foundation as Director of Research, a newly created position. She will report to Cleary Simpson, CMTRF’s CEO, and be responsible for overseeing all CMTRF-funded research and scientific programming...
CMT Research Foundation Partners with Jenny Decker, CMT Patient Attempting to Solo-Circumnavigate Globe to Raise Awareness of Charcot-Marie-Tooth Disease
The CMT Research Foundation (CMTRF) a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, has partnered with Jenny Decker, a 40-year-old nurse battling CMT, a rare neurological disease with no known cure, who last...
CMT Research Update/NMD Pharma
NMD Pharma recently published data demonstrating that their drug candidate, NMD670, improves muscle function and neuromuscular transmission deficits in both animal models and patients. Dr. William David Arnold, a member of the CMTRF Scientific Advisory Board, who was...
Vanderbilt’s Charles Sanders Successfully Finds Molecules That Alter PMP22 Production or Cell Surface Trafficking; In Next Phase Will Test if They Can Improve CMT-like Problems in Schwann Cells
CMT1A is caused by a gene-copying event that results in the overproduction of the peripheral myelin protein 22 (PMP22) in Schwann cells. The excess PMP22 protein fails to traffic normally to the cell surface and instead collects inside the cells as clumps of proteins...
CMT Research Foundation Partners to Advance Study of CMT1J by Dr. Stephan Zuchner
The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT), has partnered with the 1J Foundation, a 501(c)(3) organization dedicated to finding a cure for patients with 1J, a newly identified...
Project Update: Nanite Looks to Advance Polymer-Based Encapsulation for CMT1A
CMT 1A results from the duplication of the myelin protein 22 gene (PMP22) in Schwann cells. This causes excessive production of the PMP22 protein which disrupts the myelination process of peripheral nerves and ultimately results in axonal loss and muscle wasting over...
Cisco’s Santo Caivano Joins CMT Research Foundation Board of Directors
CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, today announced that Santo Caivano, Director, Customer Engagements of Cisco’s CAP (Critical Accounts Program) Americas team,...
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy